Orna Therapeutics
Biotech building circular RNA and LNP delivery for in vivo CAR-T cell therapies.
On the record
Checkpoint: Lilly Q2 2026 earnings call, watch for named priority on circular RNA/oRNA vs Capstan
The call
Orna's science looks protected on paper, but joining now means betting on a Lilly deal closing and ORN-252 surviving internal competition from Capstan.
Orna Therapeutics makes a new type of medicine called circular RNA that is designed to help the body's immune cells fight cancer. Eli Lilly agreed to buy the company for up to 2.4 billion dollars in February 2026, but the deal has not closed yet. The company's circular RNA approach is genuinely difficult to copy because of their patents and research data, but Orna's main medicine has never been tested in patients yet, and it will now compete inside Lilly with another similar program called Capstan. The biggest question is whether Lilly will keep Orna's program as a priority after the acquisition closes, or quietly shut it down and focus on their own approach instead.
Why
01
AI pressure: None apparent. Orna's risk is deal execution and clinical data, not AI substitution; no AI product threatens circular RNA drug delivery directly. Could AI do the core job? Unlikely.
02
Bigger players: Eli Lilly's internal Capstan mRNA platform. Lilly bought Orna's oRNA tech but also owns Capstan's competing in vivo CAR-T approach, raising odds ORN-252 gets shelved post close. Could a giant copy it? No, they are blocked.
03
What protects it. 25 filed patents plus trade secrets and in vivo validation data on oRNA circular RNA design that Lilly cannot easily replicate elsewhere.
What would change this call
Lilly names ORN-252 or oRNA as a lead priority (or omits it) in its Q2 2026 earnings call (Aug 5, 2026). Shows whether Orna's platform survives as a named priority or is folded into Capstan's approach.
Confirmed closing date and terms of the Lilly-Orna acquisition are announced. Shows whether the deal proceeds as structured or faces delay, renegotiation, or antitrust hurdles.
ORN-252 dosed first patients in a Phase 1 trial. Shows clinical de-risking of Orna's lead asset versus continued preclinical-only status.
Confirmed closing date and terms of the Lilly-Orna acquisition are announced. Shows whether the deal proceeds as structured or faces delay, renegotiation, or antitrust hurdles.
ORN-252 dosed first patients in a Phase 1 trial. Shows clinical de-risking of Orna's lead asset versus continued preclinical-only status.
Key numbers
- $2.4B Lilly acquisition agreement announced
- $221M Series B raise at $1.5B+ valuation
- $150M upfront plus $3.5B milestones from Merck
Named risks
- Lilly-Orna deal not yet confirmed closed as of July 2026, leaving antitrust and closing conditions pending.
- ORN-252 remains clinical trial-ready but had not dosed patients as of the Feb 2026 deal announcement.
- Program overlap with Lilly's own Capstan Therapeutics platform could lead to consolidation or cuts.
- Merck partnership status unresolved now that Lilly, a Merck competitor, owns Orna.
- History of repeated layoffs in Nov 2023, Dec 2023, and Nov 2024 signals ongoing cost pressure.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Capstan Therapeutics | contesting | Lilly bought Capstan in 2024 and then Orna in Feb 2026, creating internal platform overlap |
| AstraZeneca/EsoBiotec | gaining on | AstraZeneca acquired EsoBiotec's in vivo lentiviral platform for $425M+ in March 2025 |
| Umoja Biopharma | contesting | Rival lentiviral in vivo CAR-T platform (VivoVec) named among peers as of June 2026 |
| Interius BioTherapeutics | contesting | Competing lentiviral in vivo CD19/CD20 CAR-T programs INT2104/INT2106, per June 2026 landscape report |
Questions people ask
- Is Orna Therapeutics still an independent company in 2026?
- No. Eli Lilly announced a definitive agreement on February 9, 2026 to acquire Orna for up to $2.4 billion in cash. As of July 2026 the deal had not been confirmed closed, with CB Insights still listing the round as Acq-Pending, but Orna is effectively no longer independent.
- Has Orna Therapeutics dosed any patients in clinical trials?
- No. As of the February 9, 2026 Lilly acquisition announcement, Orna's lead program ORN-252, a CD19-targeting in vivo CAR-T for B-cell driven autoimmune disease, was described as clinical trial-ready but had not yet dosed patients.
- How much funding did Orna Therapeutics raise before being acquired?
- Orna raised roughly $321-322 million across at least five rounds, including a $100 million Series A in February 2021 and a $221 million Series B in August 2022 that valued the company at over $1.5 billion, according to CB Insights financial data dated 2026-02-08.
- Why did Eli Lilly buy Orna Therapeutics?
- Lilly agreed on February 9, 2026 to acquire Orna for up to $2.4 billion to advance cell therapies, gaining Orna's engineered circular RNA (oRNA) plus LNP delivery platform for in vivo CAR-T, adding to Lilly's 2024 acquisition of rival platform Capstan Therapeutics.
- Did Orna Therapeutics have layoffs?
- Yes. Orna cut staff in a defensive reduction in November 2023, its ReNAgade Therapeutics unit cut about 10% of staff in December 2023, and the combined company laid off more employees again in November 2024, per Endpoints News and STAT News reporting.
- Who are Orna Therapeutics' biggest competitors?
- Key rivals in in vivo CAR-T and circular RNA-LNP delivery include Capstan Therapeutics (acquired by Lilly in 2024), Umoja Biopharma, Interius BioTherapeutics, EsoBiotec (acquired by AstraZeneca for over $425 million in March 2025), Myeloid Therapeutics, Sana Biotechnology, and Tessera Therapeutics, per a June 2026 industry landscape report.
Timeline
- 2026-02-09Eli Lilly announces definitive agreement to acquire Orna for up to $2.4B
- 2024-11-12Combined Orna lays off staff again post-merger, per STAT News
- 2024-05-23Orna acquires ReNAgade Therapeutics; Amit Munshi becomes CEO
- 2023-12-05ReNAgade Therapeutics cuts about 10% of staff
- 2023-11-30Orna cuts staff in defensive reduction despite large funding hauls
- 2022-08-16Merck deal: $150M upfront, up to $3.5B milestones; Series B closes at $1.5B+ valuation
- 2021-02Orna closes $100M Series A round
- 2019Orna Therapeutics founded based on MIT circular RNA research
Revision history
29 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Orna Therapeutics, CB Insights (2026-05-25)
- CB Insights Financials (2026-02-08)
- BioImpact Capital press release (2022-08-16)
- Orna Therapeutics Company Profile
- PR Newswire (2024-05-23)
- Lilly to acquire Orna Therapeutics to advance cell therapies (2026-02-09)
- Merck press release (2022-08-16)
- PR Newswire (2026-02-09)
- Endpoints News (2023-11-30)
- Fierce Biotech (2023-12-05)
- STAT News (2024-11-12)
- Our Approach & Strategy